There are few data to guide best management of restenosis in this setting. We sought to evaluate the management and outcomes of restenosis after unprotected left main (ULM) stenting.
METHODS From a total sample of all patients presenting for angiography between January 2009 and December 2014 with ULM lesion > 50% (n¼ 1,363), we identified those with angiographically significant ULM in lesion restenosis (n¼42). The primary end-point was longterm rate of major adverse cardiac events (MACE) -that is death, myocardial infarction (MI) or clinically driven target lesion revascularization (TLR).
RESULTS Significant ULM lesion restenosis was identified in 43 patients (3%). The clinical indication for angiography was stable angina in 33 (78%), non ST-elevation MI in 8 (18%), ST-elevation MI in 1 (2%) and cardiac arrest in 1 (2%). The initial stenting strategy was a simple one-stent approach in 24 (56%) and a complex 2-stent technique in 19 (44%). Details of the initial stent utilized were available in 37 -drug eluting stent 29 (78 %), bare metal stent (BMS) 5 (14%) and bioresorbable vascular scaffolds 3 (8%). Restenosis was treated percutaneously in 26 patients (60%) -additional DES in 22 (84%); balloon angioplasty in 3 (12%); thromboaspiration in 1 (4%). The remaining 40% were managed surgically. Table 1 shows clinical details by treatment strategy. For those undergoing repeat PCI a simple 1-stent strategy was employed in 19 (86%).
In-hospital MACE rates was 7% with individual components of death 4.7% (2) and MI 2.3% (1). After 30þ19 months follow-up cumulative MACE rate was 23.3% comprising of death in 5 (12%), MI in 2 (4.7%) and re-TLR in 1 (2.3%). There was no reported MACE in the surgically managed group.
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Age ( CONCLUSIONS Restenosis after ULM stenting presents with a stable clinical course and can be percutaneously managed with a simple onestent strategy in the majority of cases with low repeat TLR rates. The higher MACE rates for those managed percutaneously may be explained by operator bias to treat older, more unstable patients with repeat PCI.
